Clinical Trial

Application of QDSA Platform in Cerebrovascular Diseases

Study acronym: RADAR
Recruiting
View on ClinicalTrials.gov →
Summary
Cerebrovascular diseases pose a major global public health challenge, characterized by exceptionally high mortality and disability rates, with their pathogenesis closely linked to hemodynamic abnormalities. The quantitative digital subtraction angiography (QDSA) analysis platform, leveraging its advantages of vessel modeling-free operation, high computational efficiency, and DSA-equivalent sensitivity, has emerged as a novel hemodynamic assessment method with significant clinical potential. This study aims to establish a cerebrovascular disease cohort incorporating QDSA parameters to systematically validate the clinical value of this technology in preoperative evaluation and surgical planning, thereby providing evidence-based insights for optimizing diagnostic and therapeutic strategies.
Trial Details
NCT Number NCT06902415
Lead Sponsor Beijing Tiantan Hospital
Conditions Cerebrovascular Disease
Enrollment 1,000 participants
Start Date 2025-04
Primary Completion 2030-02 (estimated)
Study Completion 2030-02 (estimated)
Updated on ClinicalTrials.gov 2025-03-30